Table of contents
January 2005 Vol 4 No 1
In this issue
p1 | doi:10.1038/nrd1620
Editorial: Escaping Castalia
p3 | doi:10.1038/nrd1622
News and Analysis
News
How to avoid another 'Vioxx' | PDF (158 KB)
p5 | doi:10.1038/nrd1629
News in Brief
Novartis withdraws EU approval request | Lilly launches clinical trials registry | FDA delays release of Critical Path Initiative | Antibody treatment for MS approved | Further warnings on antidepressants | Female testosterone patch rejected by advisory committee | Calcium-channel blocker benefits halts trial | PDF (222 KB)
p7 | doi:10.1038/nrd1628
Patent watch
No more royalties for Columbia | PDF (222 KB)
p8 | doi:10.1038/nrd1624
Patent watch
Reasoning revealed behind Myriad's patent loss | PDF (222 KB)
p8 | doi:10.1038/nrd1625
Patent watch
New Act promotes collaborative research | PDF (222 KB)
p8 | doi:10.1038/nrd1626
Patent primer
Experimental support and patentability | PDF (222 KB)
p9 | doi:10.1038/nrd1613
Obituary: : Sir John Vane FRS | PDF (0KB)
p10 | doi:10.1038/nrd1627
From the analyst's couch
Rheumatoid arthritis market | PDF (254 KB)
p11 | doi:10.1038/nrd1611
Fresh from the Pipeline
Erlotinib hydrochloride | PDF (98 KB)
p13 | doi:10.1038/nrd1612
Research Highlights
Cardiovascular disease: In keeping with tradition | PDF (82 KB)
p15 | doi:10.1038/nrd1618
Heart disease: Oestrogen activates COX2 pathway | PDF (197 KB)
p16 | doi:10.1038/nrd1615
Antiviral drugs: Blocking the route to infection | PDF (117 KB)
p16 | doi:10.1038/nrd1619
Medicinal chemistry: Some things never change... | PDF (132 KB)
p17 | doi:10.1038/nrd1614
In brief
RNA interference | Cardiovascular disease | Anticancer drugs | Infectious disease | PDF (92 KB)
p18 | doi:10.1038/nrd1616
Screening: Single cell screens | PDF (92 KB)
p18 | doi:10.1038/nrd1617
Reviews
Psoriasis: emerging therapeutic strategies
Alice B. Gottlieb
p19 | doi:10.1038/nrd1607
In vivo drug discovery in the zebrafish
Leonard I. Zon & Randall T. Peterson
p35 | doi:10.1038/nrd1606
Data integration: challenges for drug discovery
David B. Searls
p45 | doi:10.1038/nrd1608
Genetic aspects of immune-mediated adverse drug effects
Peter J. Bugelski
p59 | doi:10.1038/nrd1605
Perspectives
Innovation
Multicomponent therapeutics for networked systems
Curtis T. Keith, Alexis A. Borisy & Brent R. Stockwell
p71 | doi:10.1038/nrd1609
Opinion
Macro trends in pharmaceutical innovation
Fredric J. Cohen
p78 | doi:10.1038/nrd1610
Top of page
